Charles River Laboratories International, Inc.
CRL Healthcare Diagnostics & Research
Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow CRL
Charles River Laboratories International, Inc. (CRL) Free cash flow
Charles River Laboratories International, Inc.'s free cash flow for fiscal 2025 was $518.5M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $370.6M. Over the past ten years it has ranged from $235.6M (fiscal 2017) to $532.0M (fiscal 2021); the current reading is higher than 91% of that period. Free cash flow has risen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 14th of 52 Diagnostics & Research companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $518.5M | 3.37% |
| FY2024 | $501.6M | 37.29% |
| FY2023 | $365.4M | 23.89% |
| FY2022 | $294.9M | (44.57%) |
| FY2021 | $532.0M | 40.00% |
| FY2020 | $380.0M | 11.63% |
| FY2019 | $340.4M | 13.06% |
| FY2018 | $301.1M | 27.77% |
| FY2017 | $235.6M | (9.93%) |
| FY2016 | $261.6M | 7.40% |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $148.6M | — |
| Mar 2026 | −$14.8M | — |
| Dec 2025 | $58.6M | (67.14%) |
| Sep 2025 | $178.2M | 5.28% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $1.3B |
| LH Labcorp Holdings Inc. compare | $1.2B |
| ICLR ICON PLC compare | $883.8M |
| MEDP Medpace Holdings, Inc. compare | $706.7M |
| RVTY Revvity Inc. compare | $570.2M |
| QGEN QIAGEN N.V. compare | $440.6M |
| CRL Charles River Laboratories International, Inc. | $370.6M |
| TWST Twist Bioscience Corporation compare | −$95.6M |
| GH Guardant Health, Inc. compare | −$240.7M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on CRL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement